Product image of Nitoman (Tetrabenazine) supplied by GNH India

Nitoman

Active Ingredient:
Tetrabenazine
Origin:
EU

Nitoman (Tetrabenazine)

Tetrabenazine, the active ingredient in Nitoman, is a VMAT2 inhibitor presented as an oral tablet for oral use. It is employed to manage involuntary movements associated with Huntington’s disease and to treat tardive dyskinesia in adult patients. By inhibiting vesicular monoamine transporter 2, it lowers central dopamine levels, helping to control chorea and dyskinetic movements.

GNH India supplies Nitoman as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures rigorous quality assurance and regulatory compliance for all shipments.

Manufacturer / TM Owner

Bausch Health Ireland Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Tetrabenazine is indicated for movement‑disorder conditions that involve excessive dopaminergic activity.
  • Huntington’s disease: reduces chorea and other involuntary movements, improving functional ability.
  • Tardive dyskinesia: alleviates abnormal facial and limb movements caused by long‑term antipsychotic use.

How It Works

  • Tetrabenazine selectively inhibits vesicular monoamine transporter 2 (VMAT2) in presynaptic neurons, preventing the uptake of monoamines such as dopamine, serotonin and norepinephrine into synaptic vesicles. This blockade reduces the amount of dopamine stored and released into the synaptic cleft, leading to decreased stimulation of post‑synaptic dopamine receptors and attenuation of hyperkinetic motor activity. The effect is dose‑dependent and reversible, allowing clinicians to titrate the medication to achieve optimal control of dyskinesia while monitoring for adverse effects.

Side Effects

Tetrabenazine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Drowsiness: feeling of sleepiness or reduced alertness.
  • Nausea: upset stomach and urge to vomit.
  • Fatigue: general lack of energy.
  • Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects

  • Suicidal thoughts: emergence of depression or suicidal ideation.
  • Severe depression: marked mood changes requiring immediate medical attention.
  • QT prolongation: abnormal heart rhythm that can lead to cardiac events.

Precautions & Warnings

When prescribing tetrabenazine, clinicians should observe several safety considerations to minimize risk.

  • Depression monitoring: regularly assess patients for signs of depression or suicidal behavior.
  • Cardiac evaluation: avoid use in patients with known QT prolongation or significant cardiac disease.
  • Hepatic function: adjust dose or avoid in severe liver impairment.
  • Pregnancy and lactation: use is not recommended as safety data are lacking; consider risks versus benefits.
  • Elderly caution: start at low dose and titrate slowly due to increased sensitivity.
  • Store at ambient temperature: keep tablets in original container, protect from moisture and light.

Avoid Interactions

Tetrabenazine can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

  • MAO inhibitors: risk of hypertensive crisis and serotonin syndrome.
  • CNS depressants: additive sedation and respiratory depression.
  • Antipsychotics that increase dopamine: may reduce therapeutic effect.

Moderate Interactions (Monitor Closely)

  • CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): increase tetrabenazine levels, may require dose adjustment.
  • QT‑prolonging agents (e.g., quinidine, sotalol): may enhance cardiac risk.
  • Antihypertensives: may potentiate blood pressure lowering.

Frequently Asked Questions

Nitoman contains tetrabenazine, which is prescribed for movement‑disorder conditions such as Huntington’s disease to reduce chorea and for tardive dyskinesia to lessen abnormal involuntary movements that result from long‑term antipsychotic therapy.

Tetrabenazine blocks the vesicular monoamine transporter 2 (VMAT2) in nerve terminals, preventing dopamine and other monoamines from being stored in synaptic vesicles. This reduces dopamine release into the brain, decreasing overstimulation of motor pathways and helping control hyperkinetic symptoms.

The dosage of Nitoman is individualized by the prescribing clinician based on the patient’s condition, response, and tolerability. Physicians start with a low dose and may titrate upward while monitoring efficacy and safety; exact dosing information should be obtained from the prescriber.

Safety data for tetrabenazine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk, and a healthcare professional should evaluate each case.

To request Nitoman, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nitoman (tetrabenazine) is a VMAT2 inhibitor, a different pharmacologic class from antipsychotics or dopamine antagonists that are sometimes used off‑label. Compared with older agents, tetrabenazine directly reduces dopamine storage, offering targeted control of chorea and dyskinesia but requiring careful monitoring for mood‑related side effects.

Nitoman tablets should be stored at ambient temperature, below 25 °C, in the original packaging. Protect them from moisture, excessive heat and direct light to maintain potency throughout the shelf life.

Nitoman is taken orally, usually with food to reduce gastrointestinal upset. The tablets are swallowed whole with a glass of water; they should not be crushed, chewed, or split unless specifically instructed by a healthcare professional.

The most serious risks include the development of severe depression, suicidal thoughts or behaviors, and cardiac arrhythmias such as QT prolongation. Patients should be monitored closely for mood changes and cardiac symptoms, and any concerning signs require immediate medical evaluation.

Nitoman is contraindicated in patients with known hypersensitivity to tetrabenazine, those with significant cardiac disease that predisposes to QT prolongation, and individuals with severe hepatic impairment. Caution is also advised for patients with a history of depression or suicidal ideation.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Tetrabenazine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT